PTGS2 and neoplasm: The median overall survival for patients with tumours with negligible or weak COX-2 expression was 5.3 years, while it was not achieved for patients with tumours with moderate or strong COX-2 expression: patients in this group having a lower risk of death with a hazard ratio of 0.40 (95% CI: 0.18 to 0.90).